Skip to main content

Yumanity Therapeutics, Inc. (YMTX)

NASDAQ: YMTX · IEX Real-Time Price · USD
4.22 -0.16 (-3.65%)
Nov 26, 2021 1:00 PM EST - Market closed

Company Description

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.

It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases.

Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial.

The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.

Yumanity Therapeutics, Inc.
Yumanity Therapeutics Logo
CountryUnited States
Founded2006
IPO DateFeb 11, 2016
IndustryBiotechnology
SectorHealthcare
Employees44
CEOMeenu Chhabra

Contact Details

Address:
80 Guest St Fl 5
Boston, Massachusetts 02135-2071
United States
Phone617 409 5300
Websiteproteostasis.com

Stock Details

Ticker SymbolYMTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001445283

Key Executives

NamePosition
Dr. Richard Peters M.D., Ph.D.Chief Executive Officer, President, Treasurer, Secretary and Director
Dr. Vikram Khurana M.D., Ph.D.Scientific Co-Founder and Senior Advisor of Discovery Biology
Chee Yeun Chung Ph.D.Scientific Co-Founder and Associate Director of Discovery Biology
Marie Epstein CPAVice President of Finance
Michael D. WyzgaSenior Vice President and Chief Financial Officer
Devin Whittemore SmithSenior Vice President and General Counsel
Ellen K. ForestChief Human Resources Officer
Paulash MohsenSenior Vice President and Chief Business Officer
Dr. Ajay Verma M.D., Ph.D.Executive Vice President and Head of Research & Development

Latest SEC Filings

DateTypeTitle
Nov 19, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 15, 20214Statement of changes in beneficial ownership of securities
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 15, 20218-KCurrent report
Nov 10, 2021SC 13G/AStatement of acquisition of beneficial ownership by individuals
Nov 10, 20218-KCurrent report
Aug 17, 20214Statement of changes in beneficial ownership of securities
Aug 17, 20213Initial statement of beneficial ownership of securities
Aug 16, 20218-KCurrent report
Aug 12, 202110-QQuarterly report [Sections 13 or 15(d)]
View All SEC Filings